A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Cancer
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Relapsed or Refractory Follicular Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)

Results
Download
Print

Study results

LPS GO29834 Final Results December 2022 Spanish US (PDF, 0.4 MB)

LPS GO29834 Final Results December 2022 English (PDF, 0.6 MB)

LPS GO29834 Final Results December 2022 Spanish Spain (PDF, 0.5 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study results

LPS GO29834 Final Results December 2022 Spanish US (PDF, 0.4 MB)

LPS GO29834 Final Results December 2022 English (PDF, 0.6 MB)

LPS GO29834 Final Results December 2022 Spanish Spain (PDF, 0.5 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

For the latest version of this information please go to www.forpatients.roche.com